S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Nevro (NVRO) Stock Forecast, Price & News

+1.26 (+2.73%)
(As of 05/17/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
744,332 shs
Average Volume
632,332 shs
Market Capitalization
$1.67 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Nevro logo

About Nevro

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Year Founded

Sales & Book Value

Annual Sales
$386.90 million
Book Value
$8.70 per share


Net Income
$-131.36 million
Pretax Margin




Free Float
Market Cap
$1.67 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.23 out of 5 stars

Medical Sector

323rd out of 1,426 stocks

Surgical & Medical Instruments Industry

40th out of 138 stocks

Analyst Opinion: 4.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nevro stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View analyst ratings for Nevro
or view top-rated stocks.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Nevro

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings results on Wednesday, May, 4th. The medical equipment provider reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.13. The medical equipment provider had revenue of $87.40 million for the quarter, compared to the consensus estimate of $86.19 million. Nevro had a negative net margin of 35.25% and a negative trailing twelve-month return on equity of 38.02%. Nevro's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company earned ($0.85) EPS.
View Nevro's earnings history

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $104.36 million.

What price target have analysts set for NVRO?

14 analysts have issued 1-year price targets for Nevro's stock. Their forecasts range from $64.00 to $160.00. On average, they anticipate Nevro's share price to reach $92.82 in the next year. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for Nevro
or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?
Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 62, Pay $857.84k) (LinkedIn Profile)
  • Mr. Roderick H. MacLeod, Chief Financial Officer (Age 55, Pay $458.2k)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48, Pay $437.6k) (LinkedIn Profile)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 55, Pay $482.4k)
  • Mr. Patrick Schmitz, VP of Operations (Age 62)
  • Ms. Julie D. Dewey, Chief Corp. Communications & Investor Relations Officer (Age 61)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 50)
  • Mr. Jon R. Shear, VP of Corp. Devel.
  • Ms. Lori M. Ciano, Chief HR Officer (Age 59)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 66)
What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.38%), Vanguard Group Inc. (9.22%), Wellington Management Group LLP (5.10%), Invesco Ltd. (2.95%), State Street Corp (2.28%) and Brown Advisory Inc. (1.74%). Company insiders that own Nevro stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Sei Investments Co., Jennison Associates LLC, Massachusetts Financial Services Co. MA, Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., Engineers Gate Manager LP, and Russell Investments Group Ltd.. Company insiders that have sold Nevro company stock in the last year include Leslie Stretch, Michael F Demane, and Shawn Mccormick.
View insider buying and selling activity for Nevro
or view top insider-selling stocks.

Which institutional investors are buying Nevro stock?

NVRO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Federated Hermes Inc., Woodline Partners LP, Brown Advisory Inc., Victory Capital Management Inc., Vanguard Group Inc., and Capital Fund Management S.A.. Company insiders that have bought Nevro stock in the last two years include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, and Kevin C Oboyle.
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $47.40.

How much money does Nevro make?

Nevro has a market capitalization of $1.67 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131.36 million in net income (profit) each year or ($3.900010) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 945 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.